Sugi Predict

Sugi Predict / Compounds / SCHEMBL7182840

SCHEMBL7182840

SCHEMBL7182840

Cc1cccc(Cl)c1C(=O)Pc1ccc(OC(C)(C)C)cc1.[LiH]

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ LCK P06239 2/20 0.34
▸ FABP3 P05413 1/20 0.34
▸ FABP4 P15090 1/20 0.34
▸ PPARA Q07869 3/20 0.33
▸ CYP1A2 P05177 2/20 0.33
▸ CYP3A4 P08684 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TRPM4 Q8TD43 1/20 0.33
▸ PDK1 Q15118 1/20 0.33
▸ PDK2 Q15119 1/20 0.33
▸ PDK3 Q15120 1/20 0.33
▸ PDK4 Q16654 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ TSHR P16473 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7182384 0.93 POLB (0.38) POLBLCKPPARACYP1A2CYP3A4
SCHEMBL7175205 0.91 ACACB (0.33) LCKPPARACYP1A2CYP3A4MEN1
SCHEMBL7188962 0.86 CA12 (0.39) POLBFABP4MEN1MAPTKMT2A
SCHEMBL7182030 0.85 KMT2A (0.41) TYK2POLBMAPTKMT2ATSHR
SCHEMBL7174790 0.84 TYK2 (0.34) TYK2POLBLCKFABP3FABP4
SCHEMBL7185568 0.83 FABP3 (0.40) TYK2FABP3FABP4MEN1CYP2D6
SCHEMBL7179854 0.83 TRPM4 (0.33) TYK2POLBLCKFABP3FABP4
SCHEMBL7179920 0.82 TYK2 (0.34) TYK2POLBLCKFABP3FABP4
SCHEMBL7175322 0.82 TYK2 (0.41) TYK2FABP3FABP4MAPTKMT2A
SCHEMBL7189820 0.82 MAPT (0.41) POLBMEN1MAPTKMT2ATRPM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 — — US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 — — US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 — — US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TYK2 1285/4885POLB 2322/4885LCK 1771/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 TYK2 1333/4885POLB 2993/4885LCK 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.